Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials.

[1]  K. Anstrom,et al.  Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial , 2017, JAMA.

[2]  Akshay S. Desai,et al.  Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. , 2017, JACC. Heart failure.

[3]  D. Campbell,et al.  Long-term neprilysin inhibition — implications for ARNIs , 2017, Nature Reviews Cardiology.

[4]  A. Jaffe,et al.  Natriuretic Peptides and Analytical Barriers. , 2017, Clinical chemistry.

[5]  Akshay S. Desai,et al.  Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. , 2016, Journal of the American College of Cardiology.

[6]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[7]  M. Konstam,et al.  Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials , 2016, Circulation. Heart failure.

[8]  M. Emdin,et al.  Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives. , 2016, Future cardiology.

[9]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[10]  A. Cohen-Solal,et al.  Clinical evaluation of the Heart Check system, a new quantitative measurement of fresh capillary BNP. , 2015, Biomarkers in medicine.

[11]  F. Maupas-Schwalm,et al.  Head-to-head comparison of 10 natriuretic peptide assays , 2015, Clinical chemistry and laboratory medicine.

[12]  M. Pfisterer,et al.  Which heart failure patients profit from natriuretic peptide guided therapy? A meta‐analysis from individual patient data of randomized trials , 2015, European journal of heart failure.

[13]  A. Høiseth,et al.  Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study. , 2015, Clinical chemistry.

[14]  A. Mebazaa,et al.  Unraveling N-terminal pro-B-type natriuretic peptide: another piece to a very complex puzzle in heart failure patients. , 2015, Clinical chemistry.

[15]  A. Cohen-Solal,et al.  Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure. , 2015, JACC. Heart failure.

[16]  M. Emdin,et al.  Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[17]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.

[18]  A. Mebazaa,et al.  Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. , 2014, European heart journal.

[19]  M. Pencina,et al.  Charting a roadmap for heart failure biomarker studies. , 2014, JACC. Heart failure.

[20]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[21]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[22]  R. Troughton,et al.  Natriuretic peptide-guided heart failure management. , 2014, European heart journal.

[23]  C. Watson,et al.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.

[24]  J. Burnett,et al.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. , 2013, European heart journal.

[25]  S. Solomon,et al.  Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. , 2013, JAMA.

[26]  P. Ponikowski,et al.  Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.

[27]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[28]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[29]  Eric M. Reyes,et al.  Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes: Data From Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Linked to Medicare Claims , 2011, Circulation. Heart failure.

[30]  R. McKelvie,et al.  Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial , 2011, Circulation. Heart failure.

[31]  L. Potter.  Natriuretic peptide metabolism, clearance and degradation , 2011, The FEBS journal.

[32]  Y. Ikeda,et al.  Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. , 2011, Clinical chemistry.

[33]  J. Januzzi,et al.  Natriuretic peptide testing in heart failure. , 2011, Circulation.

[34]  J. Goetze.  Biosynthesis of cardiac natriuretic peptides. , 2010, Results and problems in cell differentiation.

[35]  T. Walther,et al.  Structural substrate conditions required for neutral endopeptidase-mediated natriuretic Peptide degradation. , 2009, Journal of molecular biology.

[36]  Ahmed M Bayoumi,et al.  Improving the diagnosis of acute heart failure using a validated prediction model. , 2009, Journal of the American College of Cardiology.

[37]  A. Cohen-Solal,et al.  Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. , 2009, Journal of the American College of Cardiology.

[38]  M. Plebani,et al.  Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study , 2009, Clinical chemistry and laboratory medicine.

[39]  A. G. Semenov,et al.  Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. , 2009, Clinical chemistry.

[40]  Kent B Lewandrowski,et al.  Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. , 2008, Archives of internal medicine.

[41]  A. Jaffe,et al.  Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. , 2008, Clinical chemistry.

[42]  J. Januzzi,et al.  Biology of the natriuretic peptides. , 2008, The American journal of cardiology.

[43]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[44]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[45]  H Robert Bergen,et al.  Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[47]  M. Emdin,et al.  Endocrine paradox in heart failure: resistance to biological effects of cardiac natriuretic hormones. , 2004, Clinical chemistry.

[48]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[49]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.

[50]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[51]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.